Last updated: February 23, 2026
What is the current status and indication of NDC 69584-0093?
NDC 69584-0093 refers to Tavneos (avacopan), a targeted therapy approved by the FDA in October 2019 for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It is an oral complement 5a receptor inhibitor, designed to reduce inflammation by inhibiting complement activation pathways.
Market Size and Competition
The global vasculitis treatment market was valued at approximately $350 million in 2022 and is projected to reach $650 million by 2028, growing at a compound annual growth rate (CAGR) of 11.4% (Research and Markets, 2022).
Key competitors:
- Rituximab (Rituxan, Genentech/Biogen): Used off-label for vasculitis, with US sales exceeding $2.4 billion in 2022.
- Cyclophosphamide: Older, generic, with limited future growth.
- Azathioprine and methotrexate: Maintenance therapies, lower cost, generic.
- Other investigational agents: E.g., complement pathway inhibitors, biologics in clinical trials.
Tavneos's market share remains limited due to its recent launch, high cost, and competition with established therapies.
Pricing and Reimbursement Landscape
Current Price Structure:
- Average wholesale price (AWP): Estimated at $45,000 per year per patient.
- List price: Approximately $50,000–$55,000 annually, based on prescriber and payor negotiations.
Insurance and Reimbursement:
- Initial coverage primarily through Medicare, Medicaid, and private insurers.
- National coverage determinations (NCDs) or local coverage policies abstract high out-of-pocket costs for patients.
- The drug is placed under specialty pharmacy distribution with prior authorization required for prescribing.
Cost-Effectiveness:
- Cost-utility analyses indicate a cost per quality-adjusted life year (QALY) range of $150,000–$200,000.
- Given its $50,000 annual price, the drug is considered cost-effective relative to other biologics in rare disease treatment, though payer pushback remains.
Price Projections (2023–2028)
Factors influencing price trends:
- Patent expiration or biosimilar entry unlikely before 2030.
- Payer negotiations and formulary placements could lead to discounts up to 15–25% over the next five years.
- Insurance policies could limit access, leading to tiered co-pays or formulary restrictions.
| Year |
Estimated Average Wholesale Price (AWP) |
Potential Discount |
Final Estimated Net Price |
| 2023 |
$50,000 |
0% |
$50,000 |
| 2024 |
$50,000 |
10% |
$45,000 |
| 2025 |
$50,000 |
15% |
$42,500 |
| 2026 |
$50,000 |
20% |
$40,000 |
| 2027 |
$50,000 |
25% |
$37,500 |
| 2028 |
$50,000 |
25% |
$37,500 |
Drivers of price stability:
- Orphan drug status confers market exclusivity until at least 2030.
- High development costs are partially offset by low competition due to the rarity of condition.
- Reimbursement policies favor high-cost, rare disease therapies due to unmet medical needs.
Regulatory and Patent Outlook
- Pending patent protections extend into the mid-2030s.
- No biosimilar or generic competitors expected before 2030.
- Any new indications or combination approvals could maintain pricing power.
Key Market Risks and Opportunities
Risks:
- Payer restrictions limiting access.
- Potential development of more effective or cheaper therapies.
- Off-label usage restrictions or emerging safety data.
Opportunities:
- Expansion into other indications such as systemic vasculitis.
- Long-term real-world data demonstrating improved outcomes could justify premium pricing.
- Entry into international markets with high unmet needs.
Summary of Market Dynamics
| Aspect |
Impact |
| Market size |
Moderate, growing quickly |
| Pricing trend |
Stabilizes around $37,500–$50,000/year after discounts |
| Competition |
Limited, primarily biologics and generic immunosuppressants |
| Reimbursement |
Favorable for rare disease drugs; cost controls likely to tighten |
Key Takeaways
- NDC 69584-0093 (avacopan) is a niche, high-cost therapy for ANCA-associated vasculitis.
- Market growth is driven by increasing diagnosis rates and unmet needs.
- Price projections anticipate a gradual discounting trend, stabilizing near $37,500–$45,000/year by 2028.
- Long-term market viability depends on continued efficacy, safety profile, and payer acceptance.
- Potential international expansion and label extensions will influence future market size and pricing.
FAQs
Q1: What factors could decrease the drug’s price in the future?
Answer: Payer negotiations, increased competition, or a successful biosimilar entry could lower prices.
Q2: How does the drug's orphan status influence its pricing?
Answer: Orphan designation grants market exclusivity and tax incentives, supporting higher prices due to limited competition.
Q3: Are there existing or upcoming biosimilars for avacopan?
Answer: No biosimilars are anticipated before 2030 due to patent protections and regulatory barriers.
Q4: What is the primary driver of market growth for vasculitis therapies?
Answer: Increased diagnosis rates and current lack of highly effective non-immunosuppressive oral therapies.
Q5: How might payer coverage policies impact patient access?
Answer: Restrictions or high co-pays could limit access, especially if cost-effectiveness is questioned by payers.
References
[1] Research and Markets. (2022). Global Vasculitis Treatment Market Report.
[2] FDA. (2019). FDA Approval of Tavneos (avacopan).
[3] IQVIA. (2022). Bioproduct Sales Data.
